ProCE Banner Activity

Trastuzumab Deruxtecan: An Emerging Option for HER2-Mutated NSCLC

Clinical Thought
Are you aware of emerging options for the treatment of advanced HER2-mutated NSCLC? Read my thoughts on a new therapy showing promise to improve outcomes in these patients.

Released: October 22, 2020

Share

Faculty

Edward S. Kim

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Faculty Disclosure

Primary Author

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Edward S. Kim, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Roche, and Takeda.